Protocol EC-FV-03: A Phase II Study of EC145 in Patients With Progressive Adenocarcinoma of the Lung
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 主要终点
- Percentage of patients deriving clinical benefit
研究概览
简要总结
This is a Phase II clinical trial evaluating the benefit from therapy with vintafolide in participants with progressive adenocarcinoma of the lung.
详细描述
This is a Phase II clinical trial of vintafolide administered to participants with progressive adenocarcinoma of the lung.
Vintafolide is a drug that is specifically designed to enter cancer cells via the folate vitamin receptor (FR). Experimental evidence shows that this target receptor is expressed on a significant portion of non-small cell lung cancers. Early clinical evidence in a small number of Phase I patients suggests that vintafolide is generally well-tolerated, without many of the side-effects observed in more-standard therapeutic agents. This evidence suggests that vintafolide may be useful as a chemotherapy against progressive adenocarcinomas of the lung. The primary objective of this study is to collect data on clinical benefit produced by therapy with vintafolide .
All participants will undergo imaging with the FR targeting investigational imaging agent etarfolatide (EC20, FolateScan) during the screening period to confirm eligibility for the treatment portion of the clinical trial. Clinical evidence suggests that etarfolatide may be used to identify patients with cancers that express the target receptor.
Information about the safety and tolerability of both vintafolide and etarfolatide will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced, progressive, adenocarcinoma of the lung.
- •Previously received at least 2 cytotoxic containing chemotherapeutic regimens (can include an epidermal growth factor receptor [EGFR] inhibitor). There is no upper limit to the number of prior chemotherapeutic regimens.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •At least 4 weeks from prior therapy and recovered from associated acute toxicities.
- •Radiographic evidence of measurable disease and ertafolide "positive" tumor.
- •Adequate bone marrow reserve, hepatic, and renal function.
- •Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.
排除标准
- •Serious comorbidities (as determined by the Principal Investigator).
- •History of carcinomatous peritonitis.
- •History of severe bowel obstruction (as determined by the Principal Investigator).
- •Women who are pregnant or lactating.
- •Prior radiation therapy to assessable disease, unless disease progression is confirmed at that site.
- •Participants requiring palliative radiotherapy at time of study entry.
- •Note: Participants with central nervous system (CNS) metastasis are eligible if a) they have been treated for the CNS metastasis and have been clinically stable (with regard to their CNS disease) for >4 weeks and b) they do not require steroids or antiseizure medications (i.e., for seizure control), or if the CNS metastasis has been untreated to date, it is not associated with a midline shift or significant edema and there is no clinically-evident requirement for steroids or antiseizure medication. In either situation, participants must be off steroids and/or antiseizure medications for at least 14 days.
研究组 & 干预措施
Etarfolatide + Vintafolide
Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
干预措施: Vintafolide (Drug)
Etarfolatide + Vintafolide
Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
干预措施: Etarfolatide (Drug)
结局指标
主要结局
Percentage of patients deriving clinical benefit
时间窗: Clinical benefit is defined as the ability to receive 4 or more cycles (i.e., months) of therapy without progression of disease.
次要结局
- Tumor responses to EC145 therapy(Duration of EC145 therapy will vary according to individual participant response.)
- Progression-free survival, response duration, and overall survival time observed after EC145 therapy(2 years after completing therapy with EC145 and the 30-day follow-up period.)